A phase II proof of concept study to evalute the efficacy and safety of deep subcutaneous lanreotide Autogel 120 mg / 28 days on symptoms and healing of the esophageal and gastric mucosa in patients with gastro esophageal reflux resitant to standard therapy (combination of proton pump inhibitors and H2 antagonists)

Trial Profile

A phase II proof of concept study to evalute the efficacy and safety of deep subcutaneous lanreotide Autogel 120 mg / 28 days on symptoms and healing of the esophageal and gastric mucosa in patients with gastro esophageal reflux resitant to standard therapy (combination of proton pump inhibitors and H2 antagonists)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top